Research programme: anti-cancer therapeutics - Ascentage Pharma

Drug Profile

Research programme: anti-cancer therapeutics - Ascentage Pharma

Alternative Names: APG 2449; APG 2575; APG-1022

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Apoptosis stimulants; Proto oncogene protein c met inhibitors; Proto oncogene protein c-akt inhibitors; Proto-oncogene protein c mdm2 inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Nov 2017 Ascentage Pharma announces intention to submit IND to China FDA for APG 2449 for Non-small cell lung cancer in the first quarter 2018 (Ascentage Pharma pipeline, November 2017)
  • 10 Jan 2017 Research programme: anti-cancer therapeutics - Ascentage Pharma is available for licensing as of 10 Jan 2017. http://www.ascentagepharma.com/
  • 30 Aug 2016 Preclinical trials in Cancer in China (Unspecified) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top